Objective The best treatment option for hospitalized patients with community-acquired
pneumonia (CAP) has not been defined. The effectiveness of β-lactam/fluoroquinolone …

Community-acquired pneumonia (CAP) is a leading cause of morbidity and mortality. This
review compared two of the main treatment alternatives: quinolone or macrolide …

Current international guidelines for the management of community acquired pneumonia
(CAP) recommend therapy with a β-lactam plus a macrolide or a 'respiratory'fluoroquinolone …

Introduction Guidelines recommend respiratory fluoroquinolone monotherapy or β-lactam
plus macrolide combination therapy as first-line options for hospitalized adults with mild to …

Scope To study the factors associated with mortality in hospitalized patients with community‐
acquired pneumonia treated with monotherapy or combination therapy. Methods PubMed …

Background. Macrolides are used to treat pneumonia despite increasing antimicrobial
resistance. However, the immunomodulatory properties of macrolides may have a favorable …

Adding either macrolide or fluoroquinolone (FQ) to β-lactam has been recommended for
patients with severe community-acquired pneumonia (CAP). However, due to the limited …

The relative efficacy, safety and ecological implications of macrolides vs. quinolones in the
treatment of community-acquired pneumonia (CAP) are debatable. We performed a …

Background: For years, monotherapy with a β-lactam antibiotic (penicillin, amoxicillin or
second-generation cephalosporin) was recommended as empirical therapy for patients with …

Data comparing the treatment outcomes of the two most frequently recommended empirical
antibiotic regimens for community-acquired pneumonia (CAP)—combination therapy with an …